Market Place
Sourcing Support
Annovis Bio Reports Q3 Financial Results & Business Update
11 Nov 2024 //
GLOBENEWSWIRE
Annovis Bio Appoints Matthew Peterson as Senior Clinical Scientist
07 Nov 2024 //
GLOBENEWSWIRE
Annovis Highlights Buntanetap`s Alzheimer`s Research At CTAD
22 Oct 2024 //
GLOBENEWSWIRE
FDA Clears Annovis To Launch Phase 3 Alzheimer’s Studies
15 Oct 2024 //
GLOBENEWSWIRE
Innovative Drug Combinations Offer New Hope for Alzheimer`s and More
03 Oct 2024 //
PR NEWSWIRE
Annovis Bio Leads In Safe Neurodegenerative Disease Treatments
03 Oct 2024 //
GLOBENEWSWIRE
Annovis Bio Research Points to AD Breakthroughs
02 Oct 2024 //
GLOBENEWSWIRE
Transforming Alzheimer’s Treatment With Cognition Boosters
01 Oct 2024 //
PR NEWSWIRE
Annovis Files Patents For Buntanetap, Trulicity, & Viagra combo
30 Sep 2024 //
GLOBENEWSWIRE
Annovis Bio To Present At H.C. Wainwright Conference
05 Sep 2024 //
GLOBENEWSWIRE
Annovis Bio Reports Q2 Financial Results And Business Update
15 Aug 2024 //
GLOBENEWSWIRE
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
06 Aug 2024 //
GLOBENEWSWIRE
Annovis Bio Gets US Patent For TBI Treatment With Buntanetap
24 Jul 2024 //
GLOBENEWSWIRE
Annovis Bio FDA-Approved To Use New Buntanetap Crystal Form
16 Jul 2024 //
GLOBENEWSWIRE
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
09 Jul 2024 //
GLOBENEWSWIRE
Annovis Bio Announces New Data From Phase III Parkinson`s Study
02 Jul 2024 //
GLOBENEWSWIRE
Annovis Bio Files Provisional Patent for New Mfg Process of Crystalline
27 Jun 2024 //
GLOBENEWSWIRE
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
26 Jun 2024 //
GLOBENEWSWIRE
Annovis Bio Schedules Investor Webcast on Parkinson’s Disease Data
25 Jun 2024 //
GLOBENEWSWIRE
Annovis Highlights New Alzheimer’s Data At 2024 Alzheimer Conference
18 Jun 2024 //
GLOBENEWSWIRE
Annovis Bio’s Buntanetap Found Safe &Effective in High-Risk Alzheimer`s Patients
11 Jun 2024 //
GLOBENEWSWIRE
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
05 Jun 2024 //
GLOBENEWSWIRE
Annovis Announces New Publication in a Peer-Reviewed Journal
21 May 2024 //
GLOBENEWSWIRE
Annovis Bio Provides Updates, Announces Q1 2024 Financial Results
13 May 2024 //
GLOBENEWSWIRE
Annovis Unblinded Buntanetap Phase 3 Parkinson`s Data
09 May 2024 //
GLOBENEWSWIRE
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
06 May 2024 //
GLOBENEWSWIRE
Annovis Bio Significant Ph2/3 Data in Early Alzheimer`s
29 Apr 2024 //
GLOBENEWSWIRE
Wall Street Analysts Believe Annovis BioCould 197.98%: Here`s is How to Trade
24 Apr 2024 //
FINANCE YAHOO
Annovis Bio Provides Corporate Updates and Reports Q4 & FY23 Financial Results
02 Apr 2024 //
GLOBENEWSWIRE
Annovis Announces Publication That Supports Buntanetap`s MOA in Humans
01 Apr 2024 //
GLOBENEWSWIRE
Annovis Bio Provides Data update for the Ph II/III Study of Buntanetap in AD`s
20 Mar 2024 //
GLOBENEWSWIRE
Annovis Bio Announces Last Patient Last Visit in the Phase II/III of Buntanetap
14 Feb 2024 //
GLOBENEWSWIRE
Annovis Announces Filing of Patent Application for Treatment of Mental Illnesses
30 Jan 2024 //
GLOBENEWSWIRE
Annovis Bio Refines Timeline for Parkinsons Phase III Study Data Announcement
24 Jan 2024 //
GLOBENEWSWIRE
Annovis blames ‘data cleaning’ for ph. 3 Parkinson’s data delays
24 Jan 2024 //
FIERCE BIOTECH
Annovis Bio to Participate in the 139th Yale CEO Summit
11 Dec 2023 //
GLOBENEWSWIRE
Annovis Announces Last Patient Last Visit in the Phase III Study of Buntanetap
05 Dec 2023 //
GLOBENEWSWIRE
Annovis Bio Appoints Andrew Walsh as Vice President Finance
01 Dec 2023 //
GLOBENEWSWIRE
Annovis Announces Full Enrollment of Its Phase II/III Alzheimer™s Disease Trial
27 Nov 2023 //
GLOBENEWSWIRE
Annovis Bio Announces Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
02 Nov 2023 //
BUSINESSWIRE
Annovis Bio Announces Pricing of $7.5 Million Public Offering
31 Oct 2023 //
BUSINESSWIRE
Annovis Bio Receives Recommendation to Continue Phase 2/3 Trial of Buntanetap
30 Oct 2023 //
BUSINESSWIRE
Annovis Bio Announces Launch of Proposed Public Offering
30 Oct 2023 //
BUSINESSWIRE
Annovis Bio Showcases Promising Progress in Novel Drug Development
24 Oct 2023 //
BUSINESSWIRE
Annovis Announces Positive Independent Analysis for Alzheimer™s Study
12 Oct 2023 //
GLOBENEWSWIRE
Annovis Bio Announces Second Quarter 2023 Financial Results
15 Aug 2023 //
BUSINESSWIRE
Continued Positive Performance of Novel Drug Development by Annovis Presented
18 Jul 2023 //
BUSINESSWIRE
Annovis Bio Announces the Filing of a Groundbreaking Patent
27 Jun 2023 //
BUSINESSWIRE
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation
20 Jun 2023 //
BUSINESSWIRE
Annovis Announces Completion of PIII Parkinson`s Disease Treatment Enrollment
08 Jun 2023 //
PR NEWSWIRE
Annovis Bio Announces First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Annovis Bio Announces Issuance of U.S. Patent Covering Buntanetap
27 Apr 2023 //
GLOBENEWSWIRE
Annovis Bio To Hold Live Webcast To Review Alzheimer`S Disease Programs
13 Apr 2023 //
PR NEWSWIRE
Annovis Bio raises $8.7M for ongoing studies
11 Apr 2023 //
IRPAGES
Annovis Bio Announces Fourth Quarter And Full Year 2022 Financial Results
03 Apr 2023 //
PR NEWSWIRE
Annovis Bio approved to add further sites for Parkinson’s therapy trial
09 Feb 2023 //
CLINICAL TRIALS ARENA
Annovis Announces Approval for European Union Trial Sites for PIII of Buntanetap
08 Feb 2023 //
PR NEWSWIRE
Annovis Announces Patient Enrollment Update For Phase 3 Of Buntanetap
25 Jan 2023 //
PR NEWSWIRE
Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team
06 Jan 2023 //
PR NEWSWIRE
